InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,469.30
(
0.39%
)
US TECH 100
19,174.00
(
1.14%
)
Dow Jones
39,112.16
(
-0.76%
)
Brent Oil
84.09
(
-0.12%
)
Bitcoin
61,741.87
(
-0.10%
)
Post# of 648139
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Covid19freak

Send PM Follow Ignore
Followers 10
Posts 1253
Boards Moderated 0
Alias Born 07/20/2020

Covid19freak

Re: None

Friday, 05/05/2023 2:02:38 PM

Friday, May 05, 2023 2:02:38 PM

Post# of 648139
(TCON) $0.70 - Sarcoma final interim data in Q3 - BLA filing expected in 2024 ..Massive insider buying above $1.20+ see link below .. Positive data could push this stock toward $5

Report the second and final interim efficacy analysis from the ENVASARC pivotal trial following the review of more than 12 weeks of efficacy data (including two on-study CT scans) by the independent data monitoring committee from 46 patients who receive envafolimab as a single agent and 46 patients who receive envafolimab in combination with Yervoy®, which we expect in the third quarter of 2023.

Insider buying
http://openinsider.com/search?q=tcon
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up